RTW Biotech Opportunities (LSE:RTW) ROC (Joel Greenblatt) %: % (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:RTW RTW Biotech Opportunities Ltd LSE:RTW
41 GF Score
Price $2.41
! 2 Warning Signs
View Full Analysis

What is RTW Biotech Opportunities ROC (Joel Greenblatt) %?

RTW Biotech Opportunities LSE:RTW +0.42% 41 ROC (Joel Greenblatt) % is % as of Dec. 2025. GuruFocus rates LSE:RTW with a GF Score™ of 41/100. The stock has 2 warning signs investors should review. Among 626 Asset Management companies, RTW Biotech Opportunities ranks worse than 159744.25% on this metric.

ROC (Joel Greenblatt) % does not apply to banks and insurance companies.

LSE:RTW
41GF Score
RTW Biotech Opportunities Ltd LSE:RTW
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a ROC (Joel Greenblatt) % of % mean?
RTW Biotech Opportunities (LSE:RTW) has a ROC (Joel Greenblatt) % of % as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on RTW Biotech Opportunities and its competitors. According to the industry distribution chart, RTW Biotech Opportunities ranks #999999 out of 626 companies in the Asset Management industry.
Is RTW Biotech Opportunities' ROC (Joel Greenblatt) % too high?
RTW Biotech Opportunities' current ROC (Joel Greenblatt) % is %. Based on the distribution chart, RTW Biotech Opportunities ranks #999999 out of 626 companies in the Asset Management industry, which is in the bottom quartile relative to peers. Overall, RTW Biotech Opportunities has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does RTW Biotech Opportunities' ROC (Joel Greenblatt) % compare to BLK and BX?
According to the Asset Management industry distribution chart, RTW Biotech Opportunities ranks #999999 out of 626 companies for ROC (Joel Greenblatt) %. This places RTW Biotech Opportunities in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 64.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for an Asset Management company?
The median ROC (Joel Greenblatt) % among Asset Management companies is 64.34, based on 626 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on RTW Biotech Opportunities and its competitors. For the Asset Management industry, the median ROC (Joel Greenblatt) % is 64.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RTW Biotech Opportunities's current ROC (Joel Greenblatt) % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RTW Biotech Opportunities stock overvalued right now?
RTW Biotech Opportunities (LSE:RTW) has a current ROC (Joel Greenblatt) % of %. The current ROC (Joel Greenblatt) % is %. RTW Biotech Opportunities' overall GF Score™ is 41/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For RTW Biotech Opportunities (LSE:RTW), the current ROC (Joel Greenblatt) % is % as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RTW Biotech Opportunities Business Description

Address St Julian’s Avenue, 1st Floor, Royal Chambers, St Peter Port, GGY, GY1 3JX
RTW Biotech Opportunities Ltd is a life sciences and investment fund focused on identifying transformative assets with high growth potential across the biopharma and medtech sectors. It is powering medical breakthroughs that have the potential to transform the wellbeing of people around the world. Its portfolio includes Neurology, Oncology, Inflammation, Cardiovascular, Metabolic, Pulmonary, Ophthalmology, Rare Disease, and Other. Geographically it operates in USA & Canada, the Rest of World, and UK & EU, with the majority of the revenue deriving from USA & Canada.
41GF Score

Get the complete analysis for LSE:RTW

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.41
Price